Home›Elvitegravir Cobicistat Emtricitabine And Tenofovir Disoprox›Elvitegravir Cobicistat Emtricitabine And Tenofovir Disoprox + Famciclovir

Does Elvitegravir Cobicistat Emtricitabine And Tenofovir Disoprox Interact with Famciclovir?

CDI records a unknown classification for Elvitegravir Cobicistat Emtricitabine And Tenofovir Disoprox and Famciclovir. The stored summary is: 7.6 Drugs without Clinically Significant Interactions with STRIBILD Based on drug interaction studies conducted with the components of STRIBILD, no clinically significant drug interactions have been observed or are expected when STRIBILD is combined with the following drugs: famciclovir, famotidine, methadone, omeprazole, prasugrel (active metabolite), and sertraline. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.

Evidence status

A current label comparison is not yet available for this record. The summary and severity are stored CDI information; they have not been independently validated on this page against the exact product label.

Confirm the medicine, formulation, route, and applicable warning with your pharmacist or prescriber. Independent clinical review has not been recorded.

Stored CDI classification: Unknown
Elvitegravir Cobicistat Emtricitabine And Tenofovir Disoprox Class: Cytochrome P450 3A Inhibitor
Famciclovir Class: Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor
Management: Confirm exact products with your pharmacist
Data Source: U.S. FDA via OpenFDA

What To Tell Your Doctor or Pharmacist

If you are taking Elvitegravir Cobicistat Emtricitabine And Tenofovir Disoprox and your doctor is considering prescribing Famciclovir (or vice versa), make sure to:

Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
Ask whether the benefits of combining these medications outweigh the risks for your specific situation
Ask what symptoms to watch for that would indicate the interaction is causing problems
Never stop or change either medication without first consulting your healthcare provider

💊 Elvitegravir Cobicistat Emtricitabine And Tenofovir Disoprox(Stribild)+💊 Famciclovir(Famciclovir)

Severity & Interaction Details

ℹ️

unknown

Stored CDI classification: unknown

A current source comparison has not been recorded for this claim. The stored classification does not determine the clinical significance for your exact products or circumstances.

Severity scale

MinorContra

On record

Yes

Drug A class

Cytochrome P450 3A Inhibitor

Drug B class

Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor

Source

FDA drug label - elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate

What this means in plain English

7.6 Drugs without Clinically Significant Interactions with STRIBILD Based on drug interaction studies conducted with the components of STRIBILD, no clinically significant drug interactions have been observed or are expected when STRIBILD is combined with the following drugs: famciclovir, famotidine, methadone, omeprazole, prasugrel (active metabolite), and sertraline.

About Elvitegravir Cobicistat Emtricitabine And Tenofovir Disoprox and Famciclovir

Elvitegravir Cobicistat Emtricitabine And Tenofovir Disoprox is a Cytochrome P450 3A Inhibitor, while Famciclovir is a Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor. Elvitegravir Cobicistat Emtricitabine And Tenofovir Disoprox is also sold under the brand name Stribild. Elvitegravir Cobicistat Emtricitabine And Tenofovir Disoprox additionally carries an FDA boxed warning, the FDA's strongest safety alert.

Source and Limitations

This record was produced by automated extraction from drug-label information, including AI processing. The summary and mechanism are not verbatim FDA quotations. The drug profiles below may describe different formulations from the source label. Confirm the exact product and route with your pharmacist. This page does not establish independent clinical review.

📖 Source: FDA drug label - elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate

Recent research & FDA safety updates

Live

Auto-aggregated from PubMed E-utilities and FDA safety data.

FDA

FDA Safety Alert: Bisoprolol Fumarate and Hydrochlorothiazide tablets, USP, 2.5 mg/6.25 mg, 100-count bottle, Rx Only,about Elvitegravir Cobicistat Emtricitabine And Tenofovir Disoprox · 2026-02

PubMed

A Trial of a Single-tablet Regimen of Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Disoproxil Fumarate for the Initial Treatment of Human Immunodeficiency Virus Type 2 Infection in a Resource-limited Setting: 48-Week Results From Senegal, West Africa.about Elvitegravir Cobicistat Emtricitabine And Tenofovir Disoprox · 2018-10

PubMed

Switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir DF from non-nucleoside reverse transcriptase inhibitor plus coformulated emtricitabine and tenofovir DF regimens: Week 96 results of STRATEGY-NNRTI.about Elvitegravir Cobicistat Emtricitabine And Tenofovir Disoprox · 2017-07

Share this result:

WhatsApp Text / SMS Email

Also share on:X Facebook

Add more drugs

Check Elvitegravir Cobicistat Emtricitabine And Tenofovir Disoprox and Famciclovir against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →

How this information is prepared: CDI uses automated extraction, including AI, to summarize drug labeling from openFDA and includes separately identified curated-reference records. RxNorm helps identify medications; it does not verify interaction claims. Extracted summaries and CDI severity classifications can contain errors and are not verbatim FDA statements or independent clinical review. Maintained by CheckDrugInteractions.com. See our methodology or report a correction at support@checkdruginteractions.com.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.